tiprankstipranks
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE
Press Releases

LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

Q2 Business and Financial Highlights:

  • Net Sales were $80.9 Million
  • Gross Margin was 18%, Adjusted Gross Margin was 19%
  • Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
  • $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st

Pipeline Updates:

  • Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
  • Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
  • Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
  • Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year

TREVOSE, Pa., Feb. 1, 2023 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2023 second quarter ended December 31, 2022.

“For the quarter, net sales, gross margin and adjusted gross margin increased compared with the two preceding quarters,” said Tim Crew, chief executive officer of Lannett. “This improved performance was in part driven by higher product sales across our offering, notably, generic Adderall due to an ongoing market shortage where our partner was able to maintain their supply; the sale of certain products under a private label agreement; and less competitive intensity than we anticipated. During the quarter, we received, as expected, approximately $19 million of income tax refunds.

“With regard to our pipeline, we are nearing the launch, subject to approval, of a few products that have the potential to be meaningful contributors to our financial results. For our biosimilar insulin glargine product, initial results from the pivotal trial are expected shortly; and with regard to our biosimilar insulin aspart product, positive results from the animal study indicated that our product was highly comparable to the reference biologic. Importantly, we previously entered into a supply agreement for a pen injector delivery device for use with our biosimilar insulin glargine and biosimilar insulin aspart products. Recently we acquired a sublicense to the various patents held by the reference product owner, related to the pen injector device, thereby removing potential related litigation risk associated with the insulin glargine product and improving our ability to freely market our biosimilar insulin products, once approved.

“Looking ahead, we have raised our full-year guidance for net sales and adjusted gross margin, which reflects, in part, our improved performance over the first half of our current fiscal year and our belief that our and our partners’ reliable and high-quality supply of affordable medicines has contributed to some stabilization of our current business.”

Restructuring, Cost Reduction Initiatives

In December 2022, the company authorized a restructuring and cost savings plan that, once fully implemented, is estimated to generate cost savings of approximately $11 million, annually. The plan includes operational improvements and cost efficiencies, as well as a restructuring of the company’s research and development (R&D) function. These actions will result in a workforce reduction of approximately 60 staffed positions and 40 recently vacant positions, which will be implemented in phases over the remainder of the company’s current fiscal year. The company also anticipates exiting two facilities located in Philadelphia, Pennsylvania this year. While the plan is expected to reduce certain R&D-related costs, the company plans to maintain its level of investment in product development.

Second-Quarter Financial Results: Fiscal 2023 vs Fiscal 2022

GAAP basis:

  • Net sales were $80.9 million compared with $86.5 million
  • Gross profit was $14.3 million, or 18% of net sales, compared with $5.7 million, or 7% of net sales
  • Asset impairment charges were $6.0 million compared with $49.4 million
  • Net loss was $36.3 million, or $0.88 per share, compared with $81.1 million, or $2.01 per share

Non-GAAP basis:

  • Net sales were $80.9 million compared with $86.5 million
  • Adjusted gross profit was $15.7 million, or 19% of net sales, compared with $9.7 million, or 11% of net sales
  • Adjusted interest expense increased to $13.3 million from $12.9 million
  • Adjusted net loss was $14.0 million, or $0.34 per share compared with $15.9 million, or $0.39 per share
  • Adjusted EBITDA was $1.0 million versus negative adjusted EBITDA of $1.0 million

Guidance for Fiscal 2023

Based on its current outlook, the company raised guidance for fiscal year 2023, as follows:


GAAP

Adjusted*

Net sales

$285 million to $305 million, up from $275 million to $300 million

$285 million to $305 million, up from $275 million to $300 million

Gross margin %

Approximately 15% to 17%, up from approximately 13% to 15%

Approximately 17% to 19%, up from approximately 15% to 17%

R&D expense

$21 million to $23 million, down from $23 million to $25 million

$21 million to $23 million, down from $23 million to $25 million

SG&A expense

$66 million to $68 million, up from $64 million to $67 million

$61 million to $63 million, up from $56 million to $59 million

Restructuring expenses

$3 million to $4 million, up from $0 to $1 million

Asset impairment charges

$10.7 million, up from $4.7 million

Interest and other

Approximately $67 million, up from approximately $60 million

Approximately $53 million, unchanged

Effective tax rate

Approximately 0% to 1%, changed from approximately 0% to 4%

Approximately 20% to 22%, down from approximately 23.5% to 24.5%

(Negative) Adjusted EBITDA

N/A

($5 million) to $1 million, changed from ($12 million) to $0 million

Capital expenditures

Approximately $8 million to $10 million, changed from approximately $8 million to $12 million

Approximately $8 million to $10 million, changed from approximately $8 million to $12 million


*A reconciliation of Adjusted amounts to most directly comparable GAAP amounts can be found in the financial tables following this release.

Conference Call Information and Forward-Looking Statements

Later today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for its fiscal 2023 second quarter ended December 31, 2022. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.lannett.com. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months.

Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company’s financial status and performance, regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.

Use of Non-GAAP Financial Measures

This release contains references to non-GAAP financial measures, including Adjusted EBITDA, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP). Management uses these measures internally for evaluating its operating performance. The company’s management believes that the presentation of non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investor’s overall understanding of the financial results for the company’s core business. Additionally, it provides a basis for the comparison of the financial results for the company’s core business between current, past and future periods. The company also believes that including Adjusted EBITDA and the other non-GAAP financial measures presented in this release is appropriate to provide additional information to investors. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP. 

Detailed reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial tables following this release.

Non-GAAP financial measures exclude, among others, the effects of (1) amortization of purchased intangibles and other purchase accounting entries, (2) restructuring expenses, (3) asset impairment charges, (4) non-cash interest expense, as well as (5) certain other items considered unusual or non-recurring in nature.

NovoLog® is a registered trademark of Novo Nordisk A/S. ADVAIR DISKUS® and Flovent® Diskus® are registered trademarks of GlaxoSmithKline. Spiriva® Handihaler® is a registered trademark of Boehringer Ingelheim.

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications – see financial schedule below for net sales by medical indication. For more information, visit the company’s website at www.lannett.com.

Cautionary Statement Regarding Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and can be identified by the words “estimate,” “expect,” “believe,” “target,” “anticipate” and other similar expressions. Any such statements, including, but not limited to, statements regarding the company’s competitive environment and other market conditions; regulatory and operational developments; the timing related to commencing and successfully completing the pivotal clinical trials, filing the Biologics License Applications, and successfully launching any products, including biosimilar insulin glargine and biosimilar insulin aspart; the potential material impact of COVID-19 on future financial results; the timing of the company’s restructuring plan and its ability to realize estimated cost reductions and other benefits therefrom; the company’s financial status and performance; and the company’s ability to achieve the financial metrics stated in the company’s guidance for fiscal 2023, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors beyond the company’s control. Such factors include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, including acquired products, and the company’s estimated or anticipated future financial results, future inventory levels, future competition or pricing future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company’s latest Form 10-K, subsequent Form 8-Ks and 10-Qs and other documents filed with the Securities and Exchange Commission from time to time. You should not place undue reliance upon any such forward-looking statements, which represent the company’s judgment as of the date of this release. To the fullest extent permitted by law, the company disclaims any intent or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

FINANCIAL SCHEDULES FOLLOW

 

LANNETT COMPANY, INC.


CONSOLIDATED BALANCE SHEETS


(In thousands, except share and per share data)






(Unaudited)








December 31, 2022


June 30, 2022










ASSETS







Current assets:






Cash and cash equivalents

$                                  55,850


$                    87,854


Accounts receivable, net

80,344


56,241


Inventories


94,776


95,158


Current income taxes receivable


36,793


Assets held for sale


1,300



Other current assets


18,257


14,070


Total current assets

250,527


290,116


Property, plant and equipment, net

116,473


133,178


Intangible assets, net


29,639


32,179


Operating lease right-of-use asset 

9,274


9,646


Income taxes receivable


17,984



Other assets


14,462


19,316


TOTAL ASSETS


$                               438,359


$                  484,435


















LIABILITIES






Current liabilities:






Accounts payable


$                                  33,165


$                    29,737


Accrued expenses


25,688


23,667


Accrued payroll and payroll-related expenses

9,151


8,342


Rebates payable


21,377


21,568


Royalties payable


7,466


5,677


Restructuring liability


410


490


Current operating lease liabilities

2,074


2,064


Other current liabilities

12,885


13,395


Total current liabilities

112,216


104,940


Long-term debt, net


623,855


614,948


Long-term operating lease liabilities

9,441


9,994


Other liabilities


5,121


5,616


TOTAL LIABILITIES


750,633


735,498










STOCKHOLDERS’ DEFICIT





Common stock ($0.001 par value, 100,000,000 shares authorized; 42,996,851 and 42,269,137 shares issued;





41,247,806 and 40,704,572 shares outstanding at December 31, 2022 and June 30, 2022, respectively)

43


42


Additional paid-in capital

367,134


363,957


Accumulated deficit


(660,713)


(596,386)


Accumulated other comprehensive loss

(367)


(411)


Treasury stock (1,749,045 and 1,564,565 shares at December 31, 2022 and June 30, 2022, respectively)

(18,371)


(18,265)


Total stockholders’ deficit

(312,274)


(251,063)


TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

$                               438,359


$                  484,435










 










LANNETT COMPANY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In thousands, except share and per share data)












Three months ended 


Six months ended 



December 31,


December 31,



2022


2021


2022


2021










Net sales


$               80,894


$           86,508


$             155,973


$         188,033

Cost of sales 


65,258


76,990


126,543


157,998

Amortization of intangibles


1,358


3,808


2,553


7,804

Gross profit


14,278


5,710


26,877


22,231

Operating expenses (income):









Research and development expenses


4,928


4,747


12,107


10,511

Selling, general and administrative expenses


18,317


18,791


35,014


37,696

Restructuring expenses


335


891


481


891

Asset impairment charges


5,969


49,361


10,637


49,361

Gain on sale of intangible assets


(500)



(3,563)


Total operating expenses


29,049


73,790


54,676


98,459

Operating loss


(14,771)


(68,080)


(27,799)


(76,228)

Other income (expense), net:









Investment income


399


46


491


80

Interest expense


(15,184)


(14,430)


(30,214)


(28,654)

Loss on loan receivable


(6,826)



(6,826)


Other


106


11


87


(51)

Total other expense, net


(21,505)


(14,373)


(36,462)


(28,625)

Loss before income tax


(36,276)


(82,453)


(64,261)


(104,853)

Income tax expense (benefit)


32


(1,368)


66


(1,426)

Net loss


$             (36,308)


$         (81,085)


$              (64,327)


$        (103,427)










Loss per common share:









     Basic


$                  (0.88)


$             (2.01)


$                  (1.57)


$              (2.58)

     Diluted


$                  (0.88)


$             (2.01)


$                  (1.57)


$              (2.58)










Weighted average common shares outstanding:









     Basic


41,170,839


40,358,137


41,056,607


40,142,974

     Diluted


41,170,839


40,358,137


41,056,607


40,142,974

 

LANNETT COMPANY, INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

(In thousands, except percentages, share and per share data)


















Six months ended December 31, 2022


Net sales

Cost of sales

Amortization

of intangibles

Gross Profit

Gross

Margin

%

R&D

expenses

SG&A

expenses

Restructuring

expenses

Asset

impairment charges

Gain on sale

of intangible assets

Operating

loss

Other

expense

Loss before

income tax

Income tax

expense (benefit)

Net loss

Diluted loss

per share (k)




GAAP Reported

$        155,973

$        126,543

$             2,553

$          26,877

17 %

$          12,107

$          35,014

$                481

$          10,637

$           (3,563)

$         (27,799)

$         (36,462)

$         (64,261)

$                  66

$         (64,327)

$             (1.57)

Adjustments:

















Amortization of intangibles (a)

(2,553)

2,553


2,553

2,553

2,553


Cody API business (b)

(90)

90


(16)

106

106

106


Depreciation on capitalized software costs (c)


(2,102)

2,102

2,102

2,102


Restructuring expenses (d)


(481)

481

481

481


Asset impairment charges (e)


(10,637)

10,637

10,637

10,637


Gain on sale of intangible assets (f)


3,563

(3,563)

(3,563)

(3,563)


Non-cash interest (g)


3,637

3,637

3,637


Loss on loan receivable (h)


6,826

6,826

6,826


Other (i)


(2,603)

2,603

(140)

2,463

2,463


Tax adjustments (j)


(7,945)

7,945



















Non-GAAP Adjusted

$          155,973

$          126,453

$                    –

$            29,520

19 %

$            12,107

$            30,293

$                    –

$                    –

$                    –

$           (12,880)

$           (26,139)

$           (39,019)

$             (7,879)

$           (31,140)

$               (0.76)


















(a)

To exclude amortization of purchased intangible assets primarily related to the acquisition of KUPI 










(b)

To exclude the operating results of the ceased Cody API business












(c)

To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition









(d)

To exclude expenses primarily associated with the 2022 Restructuring Plan












(e)

To exclude asset impairment charges related to the Company’s State Road and Torresdale facilities










(f)

To exclude the gain on sale of assets related to several ANDAs, primarily purchased by Chartwell Pharmaceuticals, Inc. 









(g)

To exclude non-cash interest expense associated with debt issuance costs












(h)

To exclude the write-down of a loan receivable to a third party company operating in the online pharmaceutical business









(i)

To primarily exclude costs related to strategic review initiatives and the gain on a legal settlement










(j)

To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates











(k)

The weighted average share number for the six months ended December 31, 2022 is 41,056,607 for GAAP and non-GAAP loss per share calculations. 







 

LANNETT COMPANY, INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

(In thousands, except percentages, share and per share data)

















Six months ended December 31, 2021


Net sales

Cost of sales

Amortization

of intangibles

Gross

Profit

Gross

Margin

%

R&D

expenses

SG&A

expenses

Restructuring

expenses

Asset

impairment charges

Operating

loss

Other

expense

Loss before

income tax

Income tax

benefit

Net loss

Diluted loss

per share (j)




GAAP Reported

$        188,033

$        157,998

$             7,804

$          22,231

12 %

$          10,511

$          37,696

$                891

$          49,361

$         (76,228)

$         (28,625)

$      (104,853)

$           (1,426)

$      (103,427)

$             (2.58)

Adjustments:
















Amortization of intangibles (a)

(7,804)

7,804


7,804

7,804

7,804


Cody API business (b)

(50)

50


(6)

(270)

326

326

326


Depreciation on capitalized software costs (c)


(2,102)

2,102

2,102

2,102


Restructuring expenses (d)


(891)

891

891

891


Distribution agreement renewal costs (e)


(219)

219

219

219


Asset impairment charges (f)


(49,361)

49,361

49,361

49,361


Non-cash interest (g)


2,959

2,959

2,959


Other (h)

(177)

177


(1)

(5,944)

6,122

6,122

6,122


Tax adjustments (i)


(7,162)

7,162


















Non-GAAP Adjusted

$          188,033

$          157,771

$                    –

$            30,262

16 %

$            10,504

$            29,161

$                    –

$                    –

$             (9,403)

$           (25,666)

$           (35,069)

$             (8,588)

$           (26,481)

$               (0.66)

































(a)

To exclude amortization of purchased intangible assets primarily related to the acquisition of KUPI 









(b)

To exclude the operating results of the ceased Cody API business











(c)

To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition








(d)

To exclude expenses associated with the 2021 Restructuring Plan












(e)

To exclude the consideration recorded to renew the Company’s distribution agreement with Recro Gainesville LLC 








(f)

To exclude asset impairment charges primarily related to the KUPI product rights intangible assets and the facility and certain equipment at Silarx in Carmel, NY






(g)

To exclude non-cash interest expense associated with debt issuance costs











(h)

To primarily exclude the reimbursement of legal costs associated with a distribution agreement, one-time employee retention awards and separation costs related to the Company’s former Chief Information Officer


(i)

To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates










(j)

The weighted average share number for the six months ended December 31, 2021 is 40,142,974 for GAAP and non-GAAP loss per share calculations.






 

LANNETT COMPANY, INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

(In thousands, except percentages, share and per share data)


















Three months ended December 31, 2022


Net sales

Cost of sales

Amortization

of intangibles

Gross

Profit

Gross

Margin

%

R&D

expenses

SG&A

expenses

Restructuring

expenses

Asset

impairment charges

Gain on sale

of intangible assets

Operating

loss

Other

expense

Loss before

income tax

Income tax

expense (benefit)

Net loss

Diluted loss

per share (k)




GAAP Reported

$             80,894

$             65,258

$               1,358

$             14,278

18 %

$               4,928

$             18,317

$                335

$               5,969

$                 (500)

$           (14,771)

$           (21,505)

$           (36,276)

$                     32

$           (36,308)

$                (0.88)

Adjustments:

















Amortization of intangibles (a)

(1,358)

1,358


1,358

1,358

1,358


Cody API business (b)

(40)

40


(7)

47

47

47


Depreciation on capitalized software costs (c)


(1,051)

1,051

1,051

1,051


Restructuring expenses (d)


(335)

335

335

335


Asset impairment charges (e)


(5,969)

5,969

5,969

5,969


Gain on sale of intangible assets (f)


500

(500)

(500)

(500)


Non-cash interest (g)


1,860

1,860

1,860


Loss on loan receivable (h)


6,826

6,826

6,826


Other (i)


(1,500)

1,500

(140)

1,360

1,360


Tax adjustments (j)


(3,954)

3,954



















Non-GAAP Adjusted

$               80,894

$               65,218

$                       –

$               15,676

19 %

$                 4,928

$               15,759

$                    –

$                       –

$                       –

$               (5,011)

$             (12,959)

$             (17,970)

$               (3,922)

$             (14,048)

$                 (0.34)


















(a)

To exclude amortization of purchased intangible assets 













(b)

To exclude the operating results of the ceased Cody API business













(c)

To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition










(d)

To exclude expenses primarily associated with the 2022 Restructuring Plan












(e)

To exclude asset impairment charges related to the Company’s Torresdale facility












(f)

To exclude the gain on sale of one of the Company’s ANDAs













(g)

To exclude non-cash interest expense associated with debt issuance costs












(h)

To exclude the write-down of a loan receivable to a third party company operating in the online pharmaceutical business









(i)

To primarily exclude costs related to strategic review initiatives and the gain on a legal settlement











(j)

To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates











(k)

The weighted average share number for the three months ended December 31, 2022 is 41,170,839 for GAAP and non-GAAP loss per share calculations. 








 

LANNETT COMPANY, INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

(In thousands, except percentages, share and per share data)

















Three months ended December 31, 2021


Net sales

Cost of sales

Amortization

of intangibles

Gross

Profit

Gross

Margin

%

R&D

expenses

SG&A

expenses

Restructuring

expenses

Asset

impairment charges

Operating

loss

Other

expense

Loss before

income tax

Income

tax benefit

Net loss

Diluted loss

per share (i)




GAAP Reported

$             86,508

$             76,990

$               3,808

$               5,710

7 %

$               4,747

$             18,791

$                891

$             49,361

$           (68,080)

$           (14,373)

$           (82,453)

$              (1,368)

$           (81,085)

$                (2.01)

Adjustments:
















Amortization of intangibles (a)

(3,808)

3,808


3,808

3,808

3,808


Cody API business (b)

(17)

17


(257)

274

274

274


Depreciation on capitalized software costs (c)


(1,051)

1,051

1,051

1,051


Restructuring expenses (d)


(891)

891

891

891


Asset impairment charges (e)


(49,361)

49,361

49,361

49,361


Non-cash interest (f)


1,520

1,520

1,520


Other (g)

(177)

177


(1)

(3,525)

3,703

3,703

3,703


Tax adjustments (h)


(4,588)

4,588


















Non-GAAP Adjusted

$               86,508

$               76,796

$                       –

$                 9,712

11 %

$                 4,746

$               13,958

$                    –

$                       –

$               (8,992)

$             (12,853)

$             (21,845)

$               (5,956)

$             (15,889)

$                 (0.39)

















(a)

To exclude amortization of purchased intangible assets primarily related to the acquisition of KUPI 










(b)

To exclude the operating results of the ceased Cody API business












(c)

To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition









(d)

To exclude expenses associated with the 2021 Restructuring Plan












(e)

To exclude asset impairment charges primarily related to the KUPI product rights intangible assets and the facility and certain equipment at Silarx in Carmel, NY






(f)

To exclude non-cash interest expense associated with debt issuance costs











(g)

To primarily exclude the reimbursement of legal costs associated with a distribution agreement, one-time employee retention awards and separation costs related to the Company’s former Chief Information Officer



(h)

To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates










 


LANNETT COMPANY, INC.






RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (UNAUDITED)






($ in thousands)
















Three months ended 








December 31, 2022














Net loss


$                               (36,308)














Interest expense


15,184






Depreciation and amortization


6,287






Income tax expense


32






EBITDA


(14,805)














Share-based compensation


1,532






Inventory write-down


592






Asset impairment charges (a) 


5,969






Loss on loan receivable (b)


6,826






Investment income


(399)






Gain on sale of intangible assets (c)


(500)






Other non-operating expense


(106)






Restructuring expenses


335






Other (d) 


1,548






Adjusted EBITDA (Non-GAAP)


$                                       992













(a)

To exclude asset impairment charges related to the Company’s Torresdale facility





(b)

To exclude the write-down of a loan receivable to a third party company operating in the online pharmaceutical business


(c)

To exclude the gain on sale of one of the Company’s ANDAs





(d)

To primarily exclude costs related to strategic review initiatives 





 

 

LANNETT COMPANY, INC.






RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)






($ in millions)


















Fiscal Year 2023 Guidance














Non-GAAP










GAAP


Adjustments


Adjusted






















Net sales


 $285 – $305 



 $285 – $305 








Gross margin percentage


approx. 15% to 17%


2 %

 (a) 

approx. 17% to 19%








R&D expense


 $21 – $23 



 $21 – $23 








SG&A expense


 $66 – $68 


($5)

 (b) 

 $61 – $63 








Restructuring expenses


$3 – $4


($3 – $4)

 (c) 








Asset impairment charges


$10.7


($10.7)

 (d) 








Interest and other


 approx. $67 


($14)

 (e)  

 approx. $53 








Effective tax rate


 approx. 0% to 1% 



 approx. 20% to 22% 








Adjusted EBITDA


 N/A 


 N/A 


 $(5) – $1 








Capital expenditures


 $8 – $10 



 $8 – $10 




































(a) The adjustment primarily reflects amortization of purchased intangible assets 










(b) The adjustment primarily excludes costs related to strategic review initiatives as well as depreciation on previously capitalized software integration costs associated with the KUPI acquisition 

(c) To exclude expenses associated primarily with the 2022 Restructuring Plan










(d) To exclude asset impairment charges related to the Company’s State Road and Torresdale facilities








(e) To primarily exclude non-cash interest expense associated with debt issuance costs and the write-down of a loan receivable to a third party company operating in the online pharmaceutical business

 

 

LANNETT COMPANY, INC.





RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (UNAUDITED)





($ in millions)














Fiscal Year 2023 Guidance






Low


High













Net loss

$               (122.2)


$               (118.5)













Interest expense

60.0


60.0





Depreciation and amortization

24.0


24.0





Income taxes


(1.0)





EBITDA

(38.2)


(35.5)













Share-based compensation

6.0


6.4





Inventory write-down

6.3


7.2





Asset impairment charges (a)

10.7


10.7





Restructuring expenses (b)

3.0


4.0





Gain on sale of assets (c)

(3.6)


(3.6)





Loss on loan receivable (d)

6.8


6.8





Other (e)

4.0


5.0





Adjusted EBITDA (Non-GAAP)

$                   (5.0)


$                     1.0













(a) To exclude asset impairment charges related to the Company’s State Road and Torresdale facilities


(b) To exclude expenses associated primarily with the 2022 Restructuring Plan





(c) To exclude the gain on sale of assets related to several ANDAs, primarily purchased by Chartwell Pharmaceuticals, Inc. 

(d) To exclude the write-down of a loan receivable to a third party company operating in the online pharmaceutical business

(e) To primarily exclude costs related to strategic review initiatives 





 


LANNETT COMPANY, INC.


NET SALES BY MEDICAL INDICATION












Three months ended


Six months ended


($ in thousands)

December 31,


December 31,


Medical Indication

2022


2021


2022


2021


Analgesic

$             2,592


$             3,919


$             6,016


$             9,233


Anti-Psychosis

2,575


2,095


5,195


5,810


Cardiovascular

13,089


9,753


23,971


23,853


Central Nervous System

21,782


22,340


42,576


45,125


Endocrinology

5,831


8,297


13,143


16,142


Gastrointestinal

8,716


14,023


16,658


29,263


Infectious Disease

4,989


6,520


10,058


19,035


Migraine

3,574


4,446


6,898


9,131


Respiratory/Allergy/Cough/Cold

1,468


1,868


2,670


4,982


Other

10,955


10,275


19,714


20,627


Contract Manufacturing revenue

5,323


2,972


9,074


4,832


   Net Sales

$            80,894


$            86,508


$          155,973


$          188,033

 

Contact:

Robert Jaffe


Robert Jaffe Co., LLC


(424) 288-4098

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lannett-reports-improved-fiscal-2023-second-quarter-financial-results-raises-full-year-guidance-301736636.html

SOURCE Lannett Company, Inc.

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles